Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TESEO: New Regimens for Chagas Disease
NCT03981523Phase 2Completed
- Sponsor
- The University of Texas at El Paso
- Start
- Dec 2019
- Primary completion
- May 2024
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of benznidazole and nifurtimox in Chagas disease (6 arms), sponsored by The University of Texas at El Paso. Primary endpoint: Sustained Parasitological Clearance by qPCR at 36 months. Started Dec 2019; status: completed.
02
Drugs
benznidazolenifurtimox
03
Conditions
Chagas disease
Beyond the preview
Go deeper on NCT03981523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981523.